Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo

Abstract

Biochemical abnormalities associated with the development of multiple myeloma have been difficult to define especially in terms of demonstrating an in vivo effect of suspected lesions. Herein, we have identified such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's). In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis. Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56–267. Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis. The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in low PTEN expressing clones. Importantly, clones expressing high levels of PTEN failed to produce tumors even at five times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in tumor development in a subset of multiple myeloma patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Anderson KC, Hamblin TJ and Traynor A. . 1999 Semin. Hematol. 36: 3–8.

  • Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL and Kuehl WM. . 1996 Proc. Natl. Acad. Sci. USA 93: 13931–13936.

  • Boni R, Vortmeyer AO, Burg G, Hofbauer G and Zhuang Z. . 1998 Melanoma Res. 8: 300–302.

  • Cantley LC and Neel BG. . 1999 Proc. Natl. Acad. Sci. USA 96: 4240–4245.

  • Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK and Steck PA. . 1999 Cancer Res. 59: 2551–2556.

  • Di Cristofano A, Pesce B, Cordon-Cardo C and Pandolfi PP. . 1998 Nat. Genet. 19: 348–355.

  • Freund GG, Kulas DT, Way BA and Mooney RA. . 1994 Cancer Res. 54: 3179–3185.

  • Gabrea A, Bergsagel PL, Chesi M, Shou Y and Kuehl WM. . 1999 Mol. Cell 3: 119–123.

  • Ge N-L and Rudikoff S. . 2000 Blood in press.

  • Georgii-Hemming P, Wiklund HJ, Ljunggren O and Nilsson K. . 1996 Blood 88: 2250–2258.

  • Ghosh AK, Grigorieva I, Steele R, Hoover RG and Ray RB. . 1999 Gene 235: 85–91.

  • Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D. . 1998 Curr. Biol. 8: 1195–1198.

  • Jelinek DF, Witzig TE and Arendt BK. . 1997 J. Immunol. 159: 487–496.

  • Klein B and Bataille R. . 1992 Hematol. Oncol. Clin. North Am. 6: 273–284.

  • Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J and Bataille R. . 1990 Eur. Cytokine Netw. 1: 193–201.

  • Kyle RA. . 1992 Hematol. Oncol. Clin. North Am. 6: 347–358.

  • Ladanyi M, Wang S, Niesvizky R, Feiner H and Michaeli J. . 1992 Am. J. Pathol. 141: 949–953.

  • Li DM and Sun H. . 1997 Cancer Res. 57: 2124–2129.

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R. . 1997 Science 275: 1943–1947.

  • Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R. . 1997 Nat. Genet. 16: 64–67.

  • Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ and Eng C. . 1997 Nat. Genet. 16: 333–334.

  • Munshi NC, Barlogie B, Desikan KR and Wilson C. . 1999 Semin. Oncol. 26: 28–34.

  • Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R. . 1999 Mol. Cell. Biol. 19: 7203–7215.

  • Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B and Theillet C. . 1992 Oncogene 7: 2539–2543.

  • Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT and Neri A. . 1997 Blood 90: 4062–4070.

  • Risinger JI, Hayes AK, Berchuck A and Barrett JC. . 1997 Cancer Res. 57: 4736–4738.

  • Seiden MV and Anderson KC. . 1994 Curr. Opin. Oncol. 6: 41–49.

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV. . 1997 Nat. Genet. 15: 356–362.

  • Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M and Mak TW. . 1998 Curr. Biol. 8: 1169–1178.

  • Uddin S, Yetter A, Katzav S, Hofmann C, White MF and Platanias LC. . 1996 Exp. Hematol. 24: 622–627.

  • Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ. . 1995 Cell 80: 285–291.

  • Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K and Aokia N. . 1995 Int. J. Hematol. 62: 91–97.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ge, NL., Rudikoff, S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 19, 4091–4095 (2000). https://doi.org/10.1038/sj.onc.1203801

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203801

Keywords

This article is cited by

Search

Quick links